Sugi Predict

Sugi Predict / Compounds / SCHEMBL5520135

SCHEMBL5520135

SCHEMBL5520135

OCC1(c2ccc(Br)cn2)CC1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ TSHR P16473 2/20 0.35
▸ ADRA2A P08913 2/20 0.34
▸ ADRA2B P18089 2/20 0.34
▸ ADRA2C P18825 2/20 0.34
▸ PLAU P00749 1/20 0.34
▸ GBA1 P04062 1/20 0.34
▸ RAB9A P51151 6/20 0.34
▸ NPC1 O15118 5/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ PKM P14618 1/20 0.34
▸ OPRM1 P35372 1/20 0.34
▸ OPRL1 P41146 1/20 0.34
▸ FDPS P14324 1/20 0.33
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25259061 0.91 ALDH1A1 (0.34) ALDH1A1KDM4ETSHRADRA2AADRA2B
SCHEMBL15167242 0.88 TSHR (0.33) TSHRSMN1; SMN2OPRM1OPRL1
SCHEMBL31447991 0.83 ALDH1A1 (0.33) ALDH1A1KDM4ETSHRADRA2AADRA2B
SCHEMBL17892945 0.80 TSHR (0.44) ALDH1A1KDM4ETSHRRAB9ANPC1
SCHEMBL17080493 0.78 — —
SCHEMBL17892939 0.77 GBA1 (0.32) ALDH1A1KDM4EGBA1OPRM1OPRL1
SCHEMBL5522061 0.77 GBA1 (0.39) ALDH1A1KDM4EGBA1RAB9ANPC1
SCHEMBL15241016 0.75 OPRM1 (0.35) ALDH1A1KDM4ETSHRRAB9ANPC1
SCHEMBL17892928 0.75 RAB9A (0.39) ALDH1A1KDM4ETSHRRAB9ANPC1
SCHEMBL22289483 0.73 KDM4E (0.38) ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109119-A1 AMPK AGONISTS AND METHODS OF USE THEREOF EVVIA THERAPEUTICS INC (US) 2025-04-03 — — US disclosed
EP-4469436-A1 AMPK AGONISTS AND METHODS OF USE THEREOF Evvia Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
EP-3240542-B1 BTK INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-11-06 — — EP disclosed
EP-3240543-B1 BTK INHIBITORS MERCK SHARP & DOHME LLC (US) 2024-11-06 — — EP disclosed
WO-2023147312-A1 AMPK AGONISTS AND METHODS OF USE THEREOF EVVIA THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023147312-A1 AMPK AGONISTS AND METHODS OF USE THEREOF EVVIA THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
US-10130630-B2 BTK inhibitors MERCK SHARP & DOHME CORP. (US) 2018-11-20 — — US disclosed
EP-3114126-B1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS IDORSIA PHARMACEUTICALS LTD (CH) 2018-10-31 — — EP disclosed
US-10106544-B2 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents IDORSIA PHARMACEUTICALS LTD (CH) 2018-10-23 — — US disclosed
US-20180118766-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-03 — — US disclosed
EP-3240543-A1 BTK INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-11-08 — — EP disclosed
US-20170107223-A1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS IDORSIA PHARMACEUTICALS LTD (CH) 2017-04-20 — — US disclosed
EP-3114126-A1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Actelion Pharmaceuticals Ltd (CH) 2017-01-11 — — EP disclosed
WO-2016109215-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-07-07 — — WO disclosed
WO-2016109216-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-07-07 — — WO disclosed
WO-2015132228-A1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2015-09-11 — — WO disclosed
US-20070185132-A1 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo MERCK & CO., INC. 2007-08-09 — — US disclosed
CN-1816545-A Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof MERCK & CO INC (US) 2006-08-09 — — CN disclosed
EP-1654259-A1 CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF Merck & Co., Inc. (US) 2006-05-10 — — EP disclosed
WO-2005005420-A1 CYCLOPROPYL GROUP SUBSTITUTED OYAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK & CO., INC. (US) 2005-01-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185132-A1 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo IL17A, COASY, OXA1L ALDH1A1 1166/4885KDM4E 2970/4885TSHR 1508/4885
US-10130630-B2 BTK inhibitors BTK, SYK, LYN ALDH1A1 4304/4885KDM4E 986/4885TSHR 2090/4885
US-10106544-B2 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents CCNI, H1-0, H1-3 ALDH1A1 796/4885KDM4E 3688/4885TSHR 2525/4885
US-20180118766-A1 BTK INHIBITORS BTK, SYK, LYN ALDH1A1 4251/4885KDM4E 935/4885TSHR 2135/4885
US-20250109119-A1 AMPK AGONISTS AND METHODS OF USE THEREOF PRKAG3, PRKAG1, PRKAG2 ALDH1A1 1047/4885KDM4E 3222/4885TSHR 1463/4885
US-20170107223-A1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS CCNI, H1-0, H1-3 ALDH1A1 796/4885KDM4E 3688/4885TSHR 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.